Jack Higgins - 02 Oct 2023 Form 3 Insider Report for Immunome Inc. (IMNM)

Role
Chief Scientific Officer
Signature
/s/Sandra Stoneman, Attorney-in-Fact
Issuer symbol
IMNM
Transactions as of
02 Oct 2023
Net transactions value
$0
Form type
3
Filing time
12 Oct 2023, 18:33:15 UTC
Next filing
05 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMNM Stock Option (Right to Buy) 02 Oct 2023 Common Stock 198,564 $1.35 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares vested on May 1, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F2 Dr. Higgins was appointed as Chief Scientific Officer of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Dr. Higgins being appointed an executive officer of the Issuer, Dr. Higgins exchanged his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.

Remarks:

See Attached Exhibit 24